ArticleRevista panamericana de salud publica = Pan American journal of public health2026
[Estimated number of procedures for implementing organized screening with HPV-DNA testing in BrazilEstimaciones de procedimientos para la implementación del rastreo organizado con pruebas de ADN del VPH en Brasil].
Article in Revista panamericana de salud publica = Pan American journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Using real-world parameters, to estimate the number of procedures associated with cervical cancer to be incorporated with the implementation of organized screening with HPV-DNA testing, and to project these estimates within Brazil's Unified Health System (SUS). Methods: This is a descriptive study using data from the PREVENTIVO program in Indaiatuba, a municipality in the state of São Paulo (2017-2023), which used HPV-DNA testing to screen women aged 25 to 64 years. Based on data regarding test performance, reflex cytology, colposcopy, biopsy, cervical excisions, and referral to high-complexity care, the annual need for these procedures was estimated considering national guidelines and coverage by the supplementary private health system. These estimates were compared with the number of procedures performed nationwide in 2024 in the context of opportunistic screening with cytology (Pap smear). Results: HPV-DNA test positivity was 12.7% (3.4% for HPV16/18 and 9.3% for other high-risk HPV types). The estimated number of annual procedures to implement the program in Brazil in 2025 included: 8.2 million HPV DNA tests, 759,000 reflex cytology tests, 506,000 colposcopies, 355,000 biopsies, and 127,000 excisional procedures. Considering the current supply, there were shortfalls in all states and regions, especially for colposcopy, biopsy, and excision, with differences of up to -96.5% relative to estimated demand. Conclusion: The transition to screening with HPV DNA testing requires restructuring the supply of procedures in the SUS. The parameters presented here support regionalized planning, promoting efficient resource allocation and reducing inequities in access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.